AmplifyChange launched in 2014 as a project by a consortium consisting of MannionDaniels, African Women’s Development Fund and Global Fund for Women. Together we have run 43 funding rounds and supported 895 grants. Most of our grants (89%) are small grants to small groups, and we have other grant types available for them to form coalitions. The majority of our grants are based in Sub-Saharan Africa and South Asia and our reach also extends to the Middle East and Latin America. We have identified 25 countries that are most off-track on the AmplifyChange priorities and we do not want these countries to be overlooked. We call these ‘not-to-be-missed countries’ (NTBMC) and currently 39% of our grants have gone to ‘not-to-be-missed’ countries.
We are a challenge fund – we accept applications on a competitive basis through scheduled funding rounds. We have an independent and transparent process to assess applications. All applicants aim to empower young people, men and women to realise their sexual and reproductive health and rights.
The fund has grown from strength to strength and we have learnt important lessons about SRHR advocacy. The hard work and policy gains of our grantees are proof of the urgent need for our fund. To ensure that funds can continue to reach grassroots organisations, AmplifyChange registered as an independent not-for-profit organisation in early 2020. In November 2020 the first 61 grants were approved by the Board of the new AmplifyChange organisation. Throughout 2021 the original consortium will still be responsible for managing the grants made under the initial agreements with donors. At the same time, the not-for-profit AmplifyChange will take off fully.
The Transitional Board has approved our new 2021-2025 Strategy.
AmplifyChange wants to see transformative change in the improvement of sexual and reproductive health and rights. The pathways to change are depicted in our Theory of Change diagram.
We ask all grantees to measure and report on their progress against the five AmplifyChange outcomes.